(Q39609275)

13 September 2017

title

How I treat CML blast crisis (English)

1 reference

13 September 2017

Rüdiger Hehlmann

1

1 reference

13 September 2017

language of work or name

English

0 references

publication date

31 May 2012

1 reference

full work available at URL

13 September 2017

published in

Blood

1 reference

13 September 2017

volume

120

1 reference

13 September 2017

issue

4

1 reference

13 September 2017

page(s)

737-747

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

13 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

2 January 2025

2

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Evaluation of survival data for chronic myelocytic leukemia

2 January 2025

3

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Treatment of chronic myeloid leukemia when imatinib fails

2 January 2025

4

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Treatment of chronic myeloid leukemia in blast crisis

2 January 2025

5

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

The blast phase of chronic myeloid leukaemia

2 January 2025

6

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

2 January 2025

8

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal

2 January 2025

10

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

2 January 2025

11

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Non-random karyotypic evolution in chronic myeloid leukemia

2 January 2025

12

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

The karyotype of blastic crisis

2 January 2025

13

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.

2 January 2025

14

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

2 January 2025

15

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

2 January 2025

16

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

2 January 2025

17

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

2 January 2025

20

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.

2 January 2025

21

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

2 January 2025

22

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis.

2 January 2025

23

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Gene expression changes associated with progression and response in chronic myeloid leukemia

2 January 2025

24

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

2 January 2025

25

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia

2 January 2025

26

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia

2 January 2025

27

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

2 January 2025

28

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Specific clones of spontaneously evolving karyotypes generate individuality of cancers

2 January 2025

29

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Is carcinogenesis a form of speciation?

2 January 2025

30

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Chronic myeloid leukaemia as a model of disease evolution in human cancer

2 January 2025

31

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

The Biology of CML blast crisis

2 January 2025

32

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Chronic myeloid leukemia: mechanisms of blastic transformation

2 January 2025

33

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Oncogenic tyrosine kinases and the DNA-damage response

2 January 2025

34

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

2 January 2025

35

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks

2 January 2025

36

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

2 January 2025

37

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells

2 January 2025

38

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival

2 January 2025

39

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

2 January 2025

40

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

2 January 2025

41

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

2 January 2025

42

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

The treatment of terminal metamorphosis of chronic granulocytic leukaemia with corticosteroids and vincristine.

2 January 2025

44

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Terminal Transferase as a Predictor of Initial Responsiveness to Vincristine and Prednisone in Blastic Chronic Myelogenous Leukemia

2 January 2025

46

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis

2 January 2025

47

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

2 January 2025

48

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

2 January 2025

49

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

2 January 2025

50

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.

2 January 2025

51

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

2 January 2025

52

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

2 January 2025

54

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

2 January 2025

55

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

2 January 2025

56

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

2 January 2025

57

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

2 January 2025

58

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.

2 January 2025

59

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

2 January 2025

Bosutinib

60

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

2 January 2025

62

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

2 January 2025

63

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Current role of stem cell transplantation in chronic myeloid leukaemia

2 January 2025

64

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate

2 January 2025

65

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

The EBMT activity survey 2008: impact of team size, team density and new trends

2 January 2025

66

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis

2 January 2025

67

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

2 January 2025

68

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.

2 January 2025

69

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

2 January 2025

70

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with ima

2 January 2025

71

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

2 January 2025

73

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

2 January 2025

74

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

2 January 2025

75

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition

2 January 2025

77

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

2 January 2025

78

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo

2 January 2025

79

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells

2 January 2025

80

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

2 January 2025

81

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation

2 January 2025

82

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

2 January 2025

84

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein

2 January 2025

86

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells

2 January 2025

87

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors

2 January 2025

88

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells

2 January 2025

89

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells

2 January 2025

90

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML)

2 January 2025

91

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia

2 January 2025

93

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Experimental non-ATP-competitive therapies for chronic myelogenous leukemia

2 January 2025

94

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

The next generation of therapies for chronic myeloid leukemia

2 January 2025

95

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy

2 January 2025

97

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

2 January 2025

98

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

2 January 2025

99

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

2 January 2025

101

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

2 January 2025

102

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

2 January 2025

103

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.

2 January 2025

104

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Sequential karyotype study on Ph-positive chronic myelocytic leukemia. Significance of additional chromosomal abnormalities during disease evolution.

2 January 2025

105

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Significance of cytogenetic clonal evolution in chronic myelogenous leukemia

2 January 2025

108

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate

2 January 2025

109

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

2 January 2025

111

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate

2 January 2025

112

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

2 January 2025

113

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

2 January 2025

114

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy

2 January 2025

115

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.

2 January 2025

116

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

2 January 2025

117

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha

2 January 2025

118

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

2 January 2025

119

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data

2 January 2025

120

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

2 January 2025

123

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

2 January 2025

124

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

2 January 2025

125

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

2 January 2025

126

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

2 January 2025

127

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

2 January 2025

128

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

2 January 2025

129

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

Harmonization of molecular monitoring of CML therapy in Europe

2 January 2025

130

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2012-03-380147

2 January 2025

Identifiers

1 reference

13 September 2017

1 reference